PMID-sentid Pub_year Sent_text comp_official_name comp_offsetprotein_name organism prot_offset 21925256-3 2012 RESULTS: Andrographolide (1, 10, 100 muM) significantly down-regulates the mRNA level and protein level of CYP3A4, and inhibits nifedipine oxidation and testosterone 6beta-hydroxylation. Nifedipine 128-138 latexin Homo sapiens 37-40 22349750-7 2012 The half-maximal concentration (EC(50)) for nifedipine was 0.718 +- 0.329 muM in the accelerated group and 1.389 +- 0.482 muM in the nonaccelerated group (P = 0.009). Nifedipine 44-54 latexin Homo sapiens 74-77 22349750-8 2012 The addition of 50 muM dantrolene attenuated by 15.4% the increase in [Ca(2+)](i) caused by the 0.5 muM nifedipine. Nifedipine 104-114 latexin Homo sapiens 19-22 22349750-8 2012 The addition of 50 muM dantrolene attenuated by 15.4% the increase in [Ca(2+)](i) caused by the 0.5 muM nifedipine. Nifedipine 104-114 latexin Homo sapiens 100-103 21438692-11 2011 RESULTS: In 12 trials, extraluminal nifedipine caused aperistalsis at a concentration of 1 +- 0.1 muM, while intraluminal nifedipine needed 10.2 +- 1.1 muM. Nifedipine 36-46 latexin Homo sapiens 98-101 22004607-3 2011 Nifedipine (40 muM), taken as a positive control, showed a very similar profile. Nifedipine 0-10 latexin Homo sapiens 15-18 21471209-3 2011 Cholesterol inhibited the P450 3A4-catalyzed oxidations of nifedipine and quinidine, two prototypic substrates, in liver microsomes and a reconstituted enzyme system with K(i) ~ 10 muM in an apparently non-competitive manner. Nifedipine 59-69 latexin Homo sapiens 181-184 21438692-11 2011 RESULTS: In 12 trials, extraluminal nifedipine caused aperistalsis at a concentration of 1 +- 0.1 muM, while intraluminal nifedipine needed 10.2 +- 1.1 muM. Nifedipine 122-132 latexin Homo sapiens 152-155 21785639-7 2011 The IC50s of methanol extract, hexane fraction and curdione to oxidized nifedipine formation were 21, 14 and 3.9 mug ml(-1) (16.9 muM), respectively. Nifedipine 72-82 latexin Homo sapiens 130-133 21068071-8 2011 The L-type Ca(2+) channel inhibitor, nifedipine (10 muM), partially inhibited EST agonist and EST-induced increase in phosphorylated ERK expression. Nifedipine 37-47 latexin Homo sapiens 52-55 21126192-9 2011 Intraluminal nifedipine (1 muM) was then added to the intraluminal reservoir. Nifedipine 13-23 latexin Homo sapiens 27-30 21126192-12 2011 RESULTS: After Krebs pretreatment, intraluminal nifedipine (1 muM) significantly reduced peristaltic frequency (p = 0.0184) but did not stop peristalsis after 60 minutes of exposure in six trials. Nifedipine 48-58 latexin Homo sapiens 62-65 21126192-13 2011 After chitosan, nifedipine (1 muM) stopped ureteral peristalsis within an average of 12.30 +- 4.72 minutes. Nifedipine 16-26 latexin Homo sapiens 30-33 26530829-4 2016 Stellate-shaped PCV mural cells expressing alpha-smooth muscle actin exhibited synchronised spontaneous Ca(2+) transients to develop vasomotion which was abolished by nifedipine (1 muM), cyclopiazonic acid (10 muM), or Ca(2+)-activated Cl(-) channel inhibitors (100 muM niflumic acid, 1 muM T16Ainh-A01). Nifedipine 167-177 latexin Homo sapiens 210-213 30139243-8 2018 Mn2+ has been shown to enter cellsthrough similar mechanisms as Ca2+ but quenches fura-2 fluorescence at all excitation wavelengths.Captopril (3000 muM)-induced Mn2+ influx indirectly suggested that captopril evoked Ca2+ entry.Captopril-induced Ca2+ entry was inhibited by 15% by a protein kinase C (PKC) activator (phorbol12-myristate 13 acetate, PMA) and an inhibitor (GF109203X) and three inhibitors of store-operatedCa2+ channels: nifedipine, econazole and SKF96365. Nifedipine 435-445 latexin Homo sapiens 148-151 27988286-5 2017 Cav1 channels contribute to the exocytosis of secretory vesicles, evidenced by the block of 3muM nifedipine (36.5+-2%) of membrane capacitance increment elicited by 200ms depolarizing pulses. Nifedipine 97-107 latexin Homo sapiens 93-96 29973548-5 2018 Verapamil, nifedipine, and NiCl2 inhibited the whole-cell currents in HEK-293 cells overexpressing mTRESK with IC50 values of 5.2, 54.3, and >100 muM, respectively. Nifedipine 11-21 latexin Homo sapiens 149-152 29163064-5 2017 We found that an L-type Ca2+ channel antagonist, nifedipine, applied at concentrations of 50 muM or 100 muM to the hindlimb enlargement spinal cord, significantly reduced windup of flexion reflex motor patterns, while lower concentrations of nifedipine had no such effect. Nifedipine 49-59 latexin Homo sapiens 93-96 29163064-5 2017 We found that an L-type Ca2+ channel antagonist, nifedipine, applied at concentrations of 50 muM or 100 muM to the hindlimb enlargement spinal cord, significantly reduced windup of flexion reflex motor patterns, while lower concentrations of nifedipine had no such effect. Nifedipine 49-59 latexin Homo sapiens 104-107 26530829-4 2016 Stellate-shaped PCV mural cells expressing alpha-smooth muscle actin exhibited synchronised spontaneous Ca(2+) transients to develop vasomotion which was abolished by nifedipine (1 muM), cyclopiazonic acid (10 muM), or Ca(2+)-activated Cl(-) channel inhibitors (100 muM niflumic acid, 1 muM T16Ainh-A01). Nifedipine 167-177 latexin Homo sapiens 210-213 26530829-4 2016 Stellate-shaped PCV mural cells expressing alpha-smooth muscle actin exhibited synchronised spontaneous Ca(2+) transients to develop vasomotion which was abolished by nifedipine (1 muM), cyclopiazonic acid (10 muM), or Ca(2+)-activated Cl(-) channel inhibitors (100 muM niflumic acid, 1 muM T16Ainh-A01). Nifedipine 167-177 latexin Homo sapiens 210-213 25353059-5 2014 Nifedipine induced marked decreases in AP duration (APD): APD90 (49.8% and 40.8% of control values at 1 and 10 muM, respectively), APD50 (16.1% and 12%); cisapride 0.1 muM increased APD90 to 176.2%; and tetrodotoxin 10 muM decreased maximum slope of phase to 33.3% of control, peak depolarization potential to 76.3% of control, and shortened APD90 on average to 80.4%. Nifedipine 0-10 latexin Homo sapiens 111-114 25353059-5 2014 Nifedipine induced marked decreases in AP duration (APD): APD90 (49.8% and 40.8% of control values at 1 and 10 muM, respectively), APD50 (16.1% and 12%); cisapride 0.1 muM increased APD90 to 176.2%; and tetrodotoxin 10 muM decreased maximum slope of phase to 33.3% of control, peak depolarization potential to 76.3% of control, and shortened APD90 on average to 80.4%. Nifedipine 0-10 latexin Homo sapiens 168-171 25353059-5 2014 Nifedipine induced marked decreases in AP duration (APD): APD90 (49.8% and 40.8% of control values at 1 and 10 muM, respectively), APD50 (16.1% and 12%); cisapride 0.1 muM increased APD90 to 176.2%; and tetrodotoxin 10 muM decreased maximum slope of phase to 33.3% of control, peak depolarization potential to 76.3% of control, and shortened APD90 on average to 80.4%. Nifedipine 0-10 latexin Homo sapiens 168-171 23698119-7 2013 [Ca2+]CYT responses were blocked by removal of extracellular Ca2+ or L-type voltage-gated channel blockade with nifedipine (10 muM). Nifedipine 112-122 latexin Homo sapiens 127-130 24129906-4 2013 Ryanodine (50 muM) caused a robust, nifedipine (50 muM) independent, increase in SOCE activation to 8.6 muM/s. Nifedipine 36-46 latexin Homo sapiens 14-17 24129906-4 2013 Ryanodine (50 muM) caused a robust, nifedipine (50 muM) independent, increase in SOCE activation to 8.6 muM/s. Nifedipine 36-46 latexin Homo sapiens 51-54 24129906-4 2013 Ryanodine (50 muM) caused a robust, nifedipine (50 muM) independent, increase in SOCE activation to 8.6 muM/s. Nifedipine 36-46 latexin Homo sapiens 51-54 23941257-6 2013 KEY RESULTS: Otilonium bromide (OB) concentration dependently inhibited nifedipine-sensitive calcium transients induced by KCl (EC50 = 3.6 muM) and BayK8644 (EC50 = 4.0 muM). Nifedipine 72-82 latexin Homo sapiens 140-143 23941257-6 2013 KEY RESULTS: Otilonium bromide (OB) concentration dependently inhibited nifedipine-sensitive calcium transients induced by KCl (EC50 = 3.6 muM) and BayK8644 (EC50 = 4.0 muM). Nifedipine 72-82 latexin Homo sapiens 171-174 23869618-8 2013 Responses were also blocked by the L-type calcium channel blocker, nifedipine (1 muM), and by removal of extracellular calcium. Nifedipine 67-77 latexin Homo sapiens 81-84